An update on the pharmacological management of hyperthyroidism due to Graves' disease

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 6, 2005, Pages 851-861

  Bartalena, Luigi ^a   Tanda, Maria Laura ^a   Bogazzi, Fausto ^b   Piantanida, Eliana ^a   Lai, Adriana ^a   Martino, Enio ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Graves' disease; Hyperthyroidism; Methimazole; Propylthiouracil; Thionamides

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; INSULIN ANTIBODY; IODINE DERIVATIVE; IOPANOIC ACID; IOPODATE SODIUM; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM CARBONATE; POTASSIUM PERCHLORATE; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE DERIVATIVE; THROMBIN; THYROID HORMONE;

AGRANULOCYTOSIS; ANCA ASSOCIATED VASCULITIS; APLASTIC ANEMIA; ARTHRALGIA; BONE MARROW TOXICITY; CHOANA ATRESIA; CHOLESTASIS; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG WITHDRAWAL; EMBRYOTOXICITY; ENDOCRINE OPHTHALMOPATHY; ESOPHAGUS ATRESIA; FEVER; GASTROINTESTINAL SYMPTOM; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOGLYCEMIA; HYPOTHYROIDISM; INFECTION; LACTATION; LEUKOPENIA; LIVER NECROSIS; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; MEDICAL DECISION MAKING; NEPHROTOXICITY; PATIENT CARE; PREGNANCY; PREOPERATIVE TREATMENT; PROTEIN DEFICIENCY; PRURITUS; RECURRENT DISEASE; RELAPSE; REVIEW; SKIN APLASIA; SORE THROAT; TASTE DISORDER; THROMBOCYTOPENIA; THYROID CRISIS; THYROID HORMONE BLOOD LEVEL; THYROIDECTOMY; THYROTOXICOSIS; TITRIMETRY; TREATMENT OUTCOME; URTICARIA;

ANTITHYROID AGENTS; DISEASE MANAGEMENT; GRAVES DISEASE; HEMATOLOGIC DISEASES; HUMANS; HYPERTHYROIDISM;

EID: 21744457258     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.6.851     Document Type: Review

References (58)

1. BARTALENA L, VITTI P: Hyperthyroidism and thyrotoxicosis. In: Endocrinology and Metabolism. A Pinchera (Ed.), McGraw-Hill International Ltd., London, UK (2001):161-172.
2. MARIOTTI S, PINNA G: Autoimmune thyroid diseases. In: Diseases of the Thyroid (2nd Edition). LE Braverman (Ed.), Humana Press, Inc., Totowa, NJ, USA (2003):107-160.
3. HOW J, TOPLISS DJ, STRAKOSCH G, LEWIS M, ROW VV, VOLPE' R: T lymphocyte sensitization and suppressor T-lymphocyte defect in patients long after treatment for Graves' disease. Clin. Endocrinol. (1983) 18(1):61-71.
4. BARTALENA L, MARCOCCI C, BOGAZZI F et al.: Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N. Engl. J. Med. (1998) 338(2):73-78.
5. COOPER DS: Treatment of thyrotoxicosis. In: Werner's and Ingbar's The Thyroid - A Fundamental and Clinical Text (9th Edition). LE Braverman, RD Utiger (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2005):665-694.
6. KAPLAN MM, MEIER DA: Thionamide drug therapy. In: Graves' Disease - Pathogenesis and Treatment. BA Rapoport, S McLachlan (Eds), Kluwer Academisch Publisher, Boston, MA, USA (2000):139-152.
7. BOGAZZI F, BARTALENA L, CAMPOMORI A et al.: Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease. J. Clin. Endocrinol. Metab. (2002) 87(10):4490-4495.
8. BOGAZZI F, AGHINI-LOMBARDI F, COSCI C et al.: Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. J. Endocrinol. Invest. (2002) 25(2):176-180.
9. PANZER C, BEAZLEY R, BRAVERMAN L: Rapid preoperative preparation for severe hyperthyroid Graves' disease. J. Clin. Endocrinol. Metab. (2004) 89(5):2142-2144.
10. FONTANILLA JC, SCHNEIDER AB, SARNE DH: The use of oral radiographic contrast agents in the management of hyperthyroidism. Thyroid (2001) 11(6):561-567.
11. MARTINO E, BALZANO S, BARTALENA L et al.: Therapy of Graves' disease with sodium ipodate is associated with a high recurrecnce rate of hyperthyroidism. J. Endocrinol. Invest. (1991) 14(10):847-851.
12. MARTINO E, BARTALENA L, BOGAZZI F, BRAVERMAN LE: The effects of amiodarone on the thyroid. Endocr. Rev. (2001) 22(2):240-254.
13. COOPER DS: Antithyroid drugs. N. Engl. J. Med. (2005) 352:905-917.
14. WEETMAN AP: How antithyroid drugs works in Graves' disease. Clin. Endocrinol. (1992) 37(4):317-318.
15. BARTALENA L, BOGAZZI F, MARTINO E: Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf. (1996) 15(1):53-63.
16. ANDRES E, KURTZ JE, PERRIN AE, DUFOUR P, SCHLIENGER JL, MALOISEL F: Haematopoietic growth factor in antithyroid drug-induced agranulocytosis. QJM (2001) 94(6):423-428.
17. FUKATA S, KUMA K, SUGAWARA M: Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid (1999) 9(1):29-31.
18. MANDEL SJ, COOPER DS: The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab. (2001) 86(6):2354-2359.
19. KARLSSON FA, AXELSSON O, MELHUS H: Severe embriopathy and exposure to methimazole in early pregnancy. J. Clin. Endocrinol. Metab. (2001) 87(2):947-948.
20. PAGE SR, SHEARD CE, HERBERT M et al.: A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin. Endocrinol. (1996) 45(5):511-516.
21. WEETMAN AP: Controversy in thyroid disease. J. R. Coll. Physicians Lond. (2000) 34(4):374-380.
22. ABRAHAM P, AVENELL A, WATSON WA, PARK CM, BEVAN JS: Antithyroid drug regimen for treating Graves' hyperthyroidism (Cochrane Review). In: The Cochrane Library (Issue 4). John Wiley & Sons Ltd., Chichester, UK (2003).
23. HASHIZUME K, ICHIKAWA K, SAKURAI A et al.: Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. (1991) 324(14):947-953.
24. McIVER B, RAE P, BECKETT G, WILKINSON E, GOLD A, TOFT A: Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N. Engl. J. Med. (1996) 334(4):220-224.
25. LUCAS A, SALINAS I, RIUS F et al.: Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism? J. Clin. Endocrinol. Metab. (1997) 82(8):2410-2413.
26. RITTMASTER RS, ABBOTT EC, DOUGLAS R et al.: Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J. Clin. Endocrinol. Metab. (1998) 83(3):814-818.
27. RABER W, KMEN E, WALDHAUSL W, VIERHAPPER H: Medical therapy of Graves' disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur. J. Endocrinol. (2000) 142(2):117-124.
28. GLINOER D, DE NAYER P, BEX M, THE BELGIAN COLLABORATIVE STUDY GROUP ON GRAVES' DISEASE: Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur. J. Endocrinol. (2001) 144(5):475-483.
29. NEDREBO BG, HOLM PI, UHLVING S et al.: Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur. J. Endocrinol. (2002) 147(5):583-589.
30. HOERMANN R, QUADBECK B, ROGGENBUCK U et al.: Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Ihyroid (2002) 12(12):1119-1128.
31. MASTORAKOS G, DOUFAS AG, MANTZOS E, MANTZOS J, KOUTRAS DA: T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy. J. Endocrinol. Invest. (2003) 26(10):979-984.
32. BENKER G, REINWEIN D, KAHALY G et al.: Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. Clin. Endocrinol. (1998) 49(4):451-457.
33. MAUGENDRE D, GATEL A, CAMPION L et al.: Antithyroid drugs and Graves' disease - prospective randomized assessment of long-term treatment. Clin. Endocrinol. (1999) 50(1):127-132.
34. GREBE SK, FEEK CM, FORD RC et al.: A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin. Endocrinol. (1998) 48(5):585-592.
35. WEETMAN AP, PICKERILL AP, WATSON P, CHATTERJEE VK, EDWARDS OM: Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Quart. J. Med. (1994) 87(6):337-341.
36. VITTI P, RAGO T, CHIOVATO L et al.: Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid (1997) 7(3):369-375.
37. COSTAGLIOLA S, MORGENTHALER NG, HOERMANN R et al.: Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J. Clin. Endocrinol. Metab. (1999) 84(1):90-97.
38. ALLAHABADIA A, DAYKIN J, HOLDER RL, SHEPPARD MC, GOUGH SC, FRANKLYN JA: Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. (2000) 85(3):1038-1042.
39. KIMBALL LE, KULINSKAYA E, BROWN B, JOHNSTON C, FARID NR: Does smoking increase relapse rates in Graves' disease? J. Endocrinol. Invest. (2002) 25(2):152-157.
40. MORTIMER RH, CANNELL GR, ADDISON RS et al.: Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J. Clin. Endocrinol. Metab. (1997) 82(9):3099-3105.
41. LAFRANCHI SH, HANNA CE: Graves' disease in the neonatal period and childhood. In: Werner's and Ingbar's The Thyroid - A Fundamental and Clinical Text (9th Edition). LE Bravermal, RD Utiger (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2005):1049-1059.
42. LIPPE BM, LANDAW EM, KAPLAN SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J. Clin. Endocrinol. Metab. (1987) 64(3):1241-1247.
43. McKENZIE JM, ZAKARIJA M: Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid (1992) 2(2):155-161.
44. EARLES SM, GERRITS PM, TRANSUE DJ: Iopanoic acid in the management of neonatal Graves' disease. J. Perinatol. (2004) 24(2):105-108.
45. BARTALENA L, TANDA ML, PIANTANIDA E, LAI A, PINCHERA A: Relationship between management of hyperthyroidism and course of ophthalmopathy. J. Endocrinol. Invest. (2004) 27(3):288-294.
46. PLUMMER MF, WIERSINGA WM, MOURITS MP, KOORNNEEF L, BERGHOUT A, VAN DER GAAG R: Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol. (1989) 121(Suppl. 2):185-189.
47. MARCOCCI C, BARTALENA L, PINCHERA A: Ablative or non-ablative for Graves' hyperthyroidism in patients with ophthalmopathy? J. Endocrinol. Invest. (1998) 21(5):468-471.
48. BARTALENA L, PINCHERA A, MARCOCCI C: Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev. (2000) 21(2):168-199.
49. ANDRADE VA, GROSS JL, MAIA AL: Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. (1999) 84(11):4012-4016.
50. BRAGA M, WALPERT N, BURCH HB, SOLOMON BL, COOPER DS: The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid (2002) 12(2):135-139.
51. BONNEMA SJ, BENNEDBAEK FN, VEJE A, MARVING J, HEGEDUS L: Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J. Clin. Endocrinol. Metab. (2004) 89(9):4439-4444.
52. ALEXANDER EK, LARSEN PR: High dose of 131I for the treatment of hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol. Metab. (2002) 87(3):1073-1077.
53. BARTALENA L, BOGAZZI F, PINCHERA A, MARTINO E: Treatment with thionamides before radioiodine therapy for hyperthyroidism: yes or no? J. Clin. Endocrinol. Metab. (2005) 90(2):256.
54. BOGAZZI F, MARTINO E, BARTALENA L: Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: yes or no? J. Endocrinol. Invest. (2003) 26(2):174-176.
55. BOGAZZI F, BARTALENA L, BROGIONI S et al.: Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. (1999) 84(2):499.503.
56. SABRI O, ZIMNY M, SCHULZ G et al.: Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J. Clin. Endocrinol. Metab. (1999) 84(4):1229-1233.
57. MARCOCCI C, GIANCHECCHI D, MASINI I et al.: A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J. Endocrinol. Invest. (1990) 13(7):513-520.
58. WARTOFSKY L: Thyrotoxic storm. In: Werner's and Ingbar's The Thyroid - A Fundamental and Clinical Text (9th Edition). LE Bravermal, RDUtiger (Eds), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2005):651-657.